Introduction
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LRP-deficient mice further increases plasma FVIII, indicating that RAP-sensitive determinants other than hepatic LRP also contribute to the regulation of plasma FVIII. 13 FVIII has been reported to comprise multiple binding sites for the RAP-sensitive VLDL receptor in vitro. 14 However, we have recently demonstrated that VLDL receptor does not cooperate with LRP in FVIII clearance in vivo. 15 In the present study, we investigated the physiological role of LDLR in the catabolism of FVIII. We took advantage of unique conditional knockout mouse models for LDLR, LRP, and the combination thereof. By this approach, we identified a novel role for LDLR as a receptor that contributes to the catabolism of coagulation FVIII in vivo.
only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013 . bloodjournal.hematologylibrary.org From Construction, expression, and purification of sLDLR The construction of the adenoviral-plasmid containing full-length human LDLR cDNA has been described previously 23, 24 , and was used as a template to amplify the cDNA of the entire extracellular ligand-binding domain of LDLR (sLDLR ), comprising amino acids 22-317, by polymerase chain reaction. Oligonucleotide primers 5'-ATTCTCGAGGCAGTGGGCGACAGATGT-3' (sense) and 5'-TAAACTAGTTTCGTTGGTCCCGCACTC-5' (anti-sense) were used. This cDNA fragment was purified, digested with XhoI and SpeI, ligated into the XhoI/SpeI-digested pZEN vector 25 , and sequenced to verify the construct. The resulting plasmid contains a 16-amino acid tag (KKEDFDIYDEDENQSP) for purification, which represents the epitope of monoclonal antibody CLB-CAg 69 16, 32 , followed by the sLDLR CR1-7 coding sequence. The construct was transfected into baby hamster kidney cells as described. 25 Stable cell lines that express sLDLR were obtained by limiting dilution and protein was expressed in Optimem I medium supplemented with 100 units/mL penicillin and 100 µg/mL streptomicin. After harvesting of the medium, benzamidine (10 mM) and CaCl 2 (10 mM) were added. Purification of sLDLR CR1-7 was done by affinity-chromatography using a column of CLB-CAg 69 coupled to CNBr-Sepharose 4B as affinity matrix. This matrix was washed with 100 mM NaCl, 5 mM CaCl 2 , and 50 mM Tris (pH 7.4), and eluted with 2M NaCl, 5 mM CaCl 2 , and 50 mM Tris (pH 7.4). The obtained sLDLR CR1-7 protein was subsequently concentrated by Mono Q chromatography, using 100 mM NaCl, 5 mM CaCl 2 , and 50 mM Tris (pH 7.4) for washing and 2M NaCl, 5 mM CaCl 2 , and 50 mM Tris (pH 7.4) for elution. The preparation was dialyzed to 150 mM NaCl, 5 mM CaCl 2 , 50% (vol/vol) glycerol, and 20 mM Tris (pH 7.4), and stored at -20 °C. Purified For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From Jersey) in the same buffer. Bound IgG was detected with peroxidase-conjugated goat anti-rabbit antibody followed by staining with 3,3-diaminobenzidine.
Solid-phase binding assay
Purified recombinant sLDLR was incubated in 150 mM NaCl, 5 mM CaCl 2 , 1% (wt/vol) HSA, and 50 mM Tris (pH 7.4), in a volume of 100 µL for 2 h at 37 ºC. Bound ligand was detected by incubating with peroxidaseconjugated monoclonal antibody CLB-CAg 69 in the same buffer for 10 minutes at 37 ºC. All data were corrected for binding to control microtiter wells lacking immobilized sLDLR , RAP, LDL, or HDL, which was less than 10% relative to binding to wells containing these immobilized proteins.
Transgenic animals
Mice carrying loxP sites within the LRP gene (LRP 
Clearance of human FVIII
Human immuno-purified plasma-derived FVIII (Aafact , Sanquin Plasma Products, Amsterdam, The Netherlands) (20 international units (IU) in 200 µL) was injected into the tail vein of weight-matched male mice. At indicated time points, individual mice were serially monitored for human plasma FVIII antigen levels as described previously. 13 The amount of FVIII recovered in the plasma 1 minute after injection was 90 to 100%. Values are expressed as the percentage of FVIII remaining in the circulation, considering the amount of FVIII present at 1 minute after injection as 100%.
Pharmacokinetic parameters were calculated using a model-independent (i.e. non-compartmental)
approach. 30 A double-exponential fit was used to calculate the standard parameters area under the curve and mean residence time (MRT).
Recombinant adenovirus transduction
Recombinant adenovirus containing the human LDLR cDNA (Ad-CMV-LDLR) or -galactosidase cDNA (Ad-CMV--Gal) under the control of the cytomegalovirus promotor was generated and purified as described previously. 
Detection of LDLR in mouse liver
Mouse liver membrane extracts 13 (50 µg/lane) were subjected to nonreducing 4-15% (vol/vol) SDS-PAGE analysis, transferred to nitrocellulose membranes, and LDLR was detected as described above, only.
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Statistical analysis
In vitro data are represented as means ± standard deviation (SD). In vivo data are represented as geometric means and 68% confidence intervals (CI), which represent one SD from the geometric mean if a log-normal distribution is assumed. Data are analyzed by means of the Mann-Whitney U test. P < 0.05 was regarded as statistically significant. Table 1 ). Plasma FVIII, and to a lesser extent VWF, were increased in LRP -mice about 1.6-fold and 1.3-fold, respectively, which is in agreement with our previous findings. 13 In contrast, 32 , we found that induction of hepatic LRP-deficiency resulted in an increase of its plasma level. However, this LRP-dependent increase of plasma tPA was not affected by LDLR status (Table   1 ). These data demonstrate that LDLR knockout mice have normal plasma FVIII and VWF. In contrast, in the absence of hepatic LRP, LDLR deficiency further increases plasma FVIII and VWF.
FVIII interacts with LDLR in vitro
It has been well established that LRP comprises multiple binding sites for FVIII. 25, 33 We now , with half-maximum binding at a FVIII concentration of 156 ± 6 nM ( Figure 3A) . In contrast, FIX and the FVIII carrier protein VWF did not show any interaction with immobilized sLDLR CR1-7 ( Figure 3A ).
The specificity of FVIII binding to LDLR was addressed, using the LDLR-antagonist RAP. Indeed, FVIII binding to sLDLR CR1-7 decreased in a dose-dependent manner in the presence of increasing concentrations of RAP ( Figure 3B ). Half-maximum inhibition (K i ) occurred at a RAP concentration of about 0.9 µM, which is close to the affinity of RAP for full-length LDLR. 35 Previously, we have demonstrated that FVIII interacts with the ligand-binding cluster II of LRP. 33 Binding of FVIII to 
Adenovirus-mediated overexpression of human LDLR in mice accelerates FVIII clearance
Because FVIII binds to LDLR in vitro (Figure 3 ), the question arises whether or not LDLR is able to clear FVIII from the circulation in vivo. To this end, we employed adenovirus-mediated gene-transfer to induce hepatic overexpression of human LDLR. We injected an adenovirus containing the human LDLR cDNA (Ad-CMV-LDLR) or control adenovirus encoding the -galactosidase cDNA (Ad-CMV--Gal). It was verified that human LDLR was indeed expressed in livers of mice that received
Ad-CMV-LDLR ( Figure 4A ). As expected
23
, Ad-CMV-LDLR completely reversed the hypercholesterolemic effects in LDLR -/-mice (P = 0.002) ( Figure 4B ). Five days after adenovirus administration, plasma FVIII levels were 1.0 U/mL (CI, 0.8-1.2 U/mL) and 0.9 U/mL (CI, 0.6-1.3
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Subsequently, the same mice received an intravenous bolus injection of human FVIII and its clearance rate from plasma was monitored. The plasma removal of FVIII in Ad-CMV-LDLR-treated mice was slightly accelerated as compared with control animals that received Ad-CMV--Gal ( Figure 4C ). The MRT of FVIII was calculated to be 205 minutes in control Ad-CMV--Gal-treated mice and 141 minutes in mice that received Ad-CMV-LDLR, with 68% confidence intervals of 194-217 and 109-183 minutes, respectively (P = 0.01). These data indicate that LDLR has the potential to contribute to the clearance of FVIII from plasma in vivo.
FVIII clearance in LDLR and/or LRP knockout mice
To investigate whether the increased plasma FVIII levels in LDLR For Figure 5C ). These data indicate that, in the absence of hepatic LRP, LDLR plays a predominant role in the clearance of FVIII from the circulation.
No relation between plasma FVIII and cholesterol levels in mice
It has been well established that LDLR and LRP are of major physiological importance in plasma lipoprotein metabolism. 6 This is illustrated by increased plasma cholesterol and triglyceride levels in mice that lack LDLR, which becomes more evident when LRP and LDLR are absent in combination ( Figure 6B ). 29 Whereas huAPOCI mice had increased cholesterol and triglyceride levels, plasma FVIII was lower in huAPOCI mice than in non-transgenic controls (Table   2 ). Taken together, these data support our observation that LDLR -/-mice show elevated plasma levels of mainly apoB/E-containing LDL cholesterol and triglycerides 6, 23 , while FVIII levels remain unaffected ( 
Discussion
In the present study, we show that the level of coagulation FVIII in the circulation is regulated by a dual receptor system that not only involves LRP but also LDLR. This is compatible with our previous observation that RAP-sensitive determinants other than hepatic LRP also contribute to the catabolism of FVIII in vivo. 13 Our findings that LDLR interacts with FVIII in vitro ( Figure 3) and that LDLR plays a role in the clearance of FVIII from the circulation (Figures 4 and 5) are remarkable, because so far only 2 ligands in plasma have been identified for this receptor, namely apoE and apoB-100. 1, 2 This is in marked contrast with LRP, for which more than 35 ligands have been identified to date.
2,4
The identification of FVIII as a novel ligand of LDLR suggests that besides its well-established function in lipoprotein metabolism, this receptor may also play a previously unrecognized role in modulating hemostasis.
The importance of LDLR and LRP in FVIII catabolism is illustrated by our observation that combined deficiency of this dual receptor system in mice resulted in an approximately 4.2-fold increase of FVIII levels in plasma ( Table 1 ). The relative contribution of both receptors to FVIII catabolism remains unclear. Strikingly, mice that lack either LDLR or LRP alone displayed FVIII levels that were normal or elevated no more than 1.6-fold, respectively (Table 1 ). This implies that LDLR can functionally compensate for LRP deficiency and vice versa. The same view emerges from the pharmacokinetic experiments in these mice ( Figure 5 proposed for apoE. 40 Possibly, differences in affinity of FVIII, apoE, and/or apoB for LDLR, LRP, VLDLR, and/or HSPGs constitute an important determinant for the specificity of LDL receptor family members in vivo. 7, 8, 39, 41 In addition, this might further be related to the markedly distinct endocytosis rates that have been reported for LDLR family members (LRP > LDLR > VLDLR). 42 Another new observation from this study is that elevated plasma FVIII in LRP-deficient and LDLR -/-LRP -double knockout mice coincides with increased levels of its carrier protein VWF (Table   1 ). Because VWF has been reported not to be a ligand for LRP 7, 8 or LDLR (Figure 3 ) in vitro, it remains difficult to explain why VWF is increased in these mice. While in humans an increase of the VWF concentration in plasma often results in a concomitant rise of FVIII, this is not the case in mice. 13, 43, 44 One might conclude that the observed increases in VWF levels are the direct result of elevated plasma FVIII. However, further research is required to elucidate the molecular mechanism behind the elevated levels of plasma VWF in mice that lack both hepatic LRP and LDLR.
High levels of FVIII in plasma (> 1.5 U/mL) constitute a major risk factor for both arterial and venous thrombosis in humans. 10, 11 Our observation that upregulation of hepatic LDLR protein expression in mice by gene-transfer accelerated FVIII clearance from the circulation (Figures 4 and 5) may be of therapeutic interest for patients that suffer from elevated plasma FVIII. In humans, upregulation of LDLR protein is achieved by treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, also called statins. 3 Currently, statins are widely recognized in the treatment of human hypercholesterolemia. 3 It would be interesting to study whether or not statins have only.
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